Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Johnson & Johnson (JNJ) AI Forecast

Our AI ranks Johnson & Johnson outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$JNJ Bearish Signal Full forecast available

Johnson & Johnson (JNJ) Stock Forecast Sept. 24, 2026


Johnson & Johnson (JNJ) AI Stock Price Forecast & Investment Analysis

Johnson & Johnson Stock Price Chart and Technical Analysis

Loading chart...

Johnson & Johnson (JNJ) - Comprehensive Stock Analysis & Investment Research

Deep dive into Johnson & Johnson's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Johnson & Johnson Investment Summary

When evaluating whether Johnson & Johnson (JNJ) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Johnson & Johnson (JNJ) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $649 billion, the company is classified as a mega-cap stock, typically characterized by high stability and strong institutional backing.

Financial Performance Analysis

Our comprehensive financial analysis covers Johnson & Johnson's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Johnson & Johnson along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Johnson & Johnson is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Johnson & Johnson

Sign Up Free
Corporate Identity

Johnson & Johnson (Stock Symbol: JNJ) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Johnson & Johnson's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Johnson & Johnson...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Johnson & Johnson...

Unlock Full Company Profile

Get complete details about Johnson & Johnson

Sign Up Free
Revenue & Growth Analysis

Johnson & Johnson generates annual revenues of $98 billion , demonstrating substantial market presence and operational scale.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Johnson & Johnson...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Johnson & Johnson...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Johnson & Johnson...

Unlock Financial Analysis

Get complete financial metrics for Johnson & Johnson

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Johnson & Johnson's AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Johnson & Johnson strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mega-cap market leader, the company commands significant market influence, enjoying substantial competitive moats including brand recognition, scale economies, and extensive distribution networks. Mega-cap status typically brings advantages in capital access, talent acquisition, and partnership opportunities, while also attracting the highest levels of institutional investor and analyst coverage.

Industry Competitive Landscape

Johnson & Johnson competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company demonstrates exceptional operational efficiency through free cash flow generation of $22 billion annually , with year-over-year cash flow growth of 19.9%. This substantial cash generation capability provides significant strategic flexibility for acquisitions, share repurchases, dividend growth, or debt reduction—all while maintaining operational investments necessary to defend market position.

Margin & Pricing Power Analysis

The company maintains a 67.9% gross margin which reflects strong pricing power and/or low direct production costs relative to revenue. Gross margins are only comparable within an industry, so read this level against the company's peers rather than the market as a whole.

Asset Utilization Efficiency

Asset turnover ratio of 0.49x indicates moderate asset turnover. Lower turnover is expected where the business model requires significant infrastructure, so the ratio should be read against the company's own industry.

Financial Strength & Leverage

Current ratio of 1.09 suggests tight liquidity where current assets just cover current liabilities. This may be efficient but leaves limited cushion for unexpected needs.

Johnson & Johnson (JNJ) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Johnson & Johnson stock analysis.

Deep dive into Johnson & Johnson's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Johnson & Johnson stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Johnson & Johnson: With a P/E ratio of 30.83, the market highly values future growth prospects.

P/E Ratio 30.83x
P/B Ratio 7.63x
Market Cap $648.67B
Dividend Yield 1.95%
EPS $8.61
Book Value/Share $35.26
Revenue/Share $40.64
FCF/Share $9.23
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Johnson & Johnson converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Johnson & Johnson: An ROE of 24.8% demonstrates excellent shareholder value creation.

ROE 24.8%
ROA 10.5%
Gross Margin 67.9%
Net Margin 21.5%
EBT Margin 25.7%
Tax Rate 16.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Johnson & Johnson's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Johnson & Johnson: A current ratio of 1.09 shows adequate liquidity.

Current Ratio 1.09x
Quick Ratio 0.81x
D/E Ratio 1.37x
Financial Leverage 2.37x
Interest Coverage 42.2x
Working Capital $4.88B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Johnson & Johnson's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Johnson & Johnson: Free cash flow of $22244M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $27.61B
Free Cash Flow $22.24B
Capital Spending -$5.36B
OCF Growth YoY 19.9%
FCF Growth YoY 19.9%
FCF/Sales 22.7%
CapEx/Sales 5.5%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Johnson & Johnson uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Johnson & Johnson: An asset turnover of 0.49x suggests room for improvement in asset utilization.

Asset Turnover 0.49x
Receivables Turnover 5.1x
Inventory Turnover 2.1x
Fixed Assets Turnover 4.2x
Days Sales Outstanding 71 days
Days Inventory 176 days
Payables Period 107 days
Cash Conversion Cycle 140 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Johnson & Johnson's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Johnson & Johnson: With annual revenue of $97929M, Johnson & Johnson operates at significant scale.

Income Statement
Total Revenue $97.93B
Net Income $21.04B
R&D Expense $548M
SG&A Expense $25.14B
Cost of Goods Sold $31.43B
Balance Sheet Highlights (USD millions, 2026-06-28)
Total Current Assets $59.77B (29.7% of assets)
Cash & Short-term Investments $20.42B (10.2% of assets)
Accounts Receivable $19.05B (9.5% of assets)
Inventory $15.14B (7.5% of assets)
Total Liabilities $116.09B (57.7% of assets)
Short-term Debt $45.67B (22.7% of assets)
Dividend & Shareholder Information
Dividends Per Share $5.24
Payout Ratio 60.9%
Shares Outstanding 2410M

Latest Johnson & Johnson Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Johnson & Johnson (JNJ) stock price and investment outlook.

📰 Loading...

Where JNJ sits on the market map

Explore the map →

Johnson & Johnson Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Johnson & Johnson (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
JNJ ██% $648.67B 30.8x 7.6x
LLY ██% $1.08T 40.6x 110.2x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Johnson & Johnson Stock Forecast

How accurate are Johnson & Johnson stock predictions?

For JNJ, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 36.0%, measured on 358 forecast dates between 2022-07-07 and 2026-06-26 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -5.0%, measured on 400 forecast dates between 2022-07-07 and 2026-08-25. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Johnson & Johnson stock price forecasts?

Our analysis considers Johnson & Johnson's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Johnson & Johnson a good investment in 2026?

Based on our AI analysis, Johnson & Johnson shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Johnson & Johnson forecasts updated?

Johnson & Johnson forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Johnson & Johnson?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...